Glucose-6-phosphatase Inhibitors
1 drugsAbout Glucose-6-phosphatase
Glucose-6-phosphatase (G6Pase) is a key enzyme in glucose homeostasis, catalyzing the final step in gluconeogenesis and glycogenolysis. It hydrolyzes glucose-6-phosphate to glucose, maintaining blood glucose levels during fasting and energy demands.
G6Pase represents a potential drug target due to its central role in glucose regulation. Currently, there is no genetic evidence available linking G6Pase to specific diseases, indicating an early stage of target validation.
G6Pase is targeted by one FDA-approved drug, fludeoxyglucose F18, a small molecule marketed by PETNET. This single drug is approved for 'other' therapeutic areas.
Top Glucose-6-phosphatase Drugs
PETNET is the only company with an approved drug targeting G6Pase.
Low competition may present an opportunity, but also indicates potential challenges in market viability.
Glucose-6-phosphatase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Glucose-6-phosphatase, using small molecule modality.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing therapies.
Glucose-6-phosphatase Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Glucose-6-phosphatase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 2 | 2 | 0 | 50% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Glucose-6-phosphatase Drug Approval Timeline (1994 - 1994)
Evaluation of malignancy in patients with known or suspec...
The first and most recent drug approval for G6Pase was in 1994 (fludeoxyglucose F18).
The lack of recent approvals suggests a saturated market or challenges in developing new G6Pase-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Glucose-6-phosphatase. A trial counts if an approved drug acting on Glucose-6-phosphatase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.